Services often involve, but are not limited to:
- Best-in-class drug property identification
- Mechanistic PK/PD modeling
- Knowledge gap analysis
- Experiment prioritization and design
- GLP toxicity study design and analysis
- First-in-human starting dose projection
- Noncompartmental analysis
- Species translation
- Technical due diligence for in-licensing opportunities
- Portfolio prioritization
- Disease model development
- Combination therapy
Applied BioMath’s early discovery services help drug development teams assess the likelihood that a drug candidate can be developed for a drug target. Questions such as whether the candidate will meet the desired route of administration and dosing schedules, whether the target should be the ligand or the receptor, as well as critical Go/No-go decisions around whether to pursue the proposed target are assessed. This helps identify failures early and prioritize what experiments are necessary moving forward, ultimately reducing project timelines and cost.
Applied BioMath offers support for GLP-toxicology studies through Phase 2, including pre-IND and IND reports as well as pharmacoeconomics. We help design clinical trials by determining patient selection, sample collection times, biomarker selection, and how high and what frequency of a dose is required to assess proof of clinical concept. Our models also help you accurately predict first-in-human doses.